Efalizumab for subacute cutaneous lupus: report of two different outcomes.
Sánchez-Cano
D
D
Callejas-Rubio
J L
JL
Ríos-Fernández
R
R
Gutiérrez-Salmerón
M T
MT
Fernández Pugnaire
M A
MA
Ortego-Centeno
N
N
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab